Hedrin Spray Gel

with 1 hour treatment time

Available from your pharmacist
and in-store medicine aisle

Hedrin range    Availability

Hedrin logo bar

About Hedrin 4% Lotion

Efficacy

Hedrin treated louse suffers gut rupture

Hedrin is the UK's first licensed product specifically formulated to kill head lice without the resistance which can sometimes be associated with traditional insecticides, which act by poisoning the louse.

Its revolutionary formulation is based on Dimeticone, which acts as a physical inhibitor by smothering the louse, preventing its ability to excrete surplus water. One of the largest clinical studies ever conducted on head lice has proven that Hedrin is an effective method of lice eradication.¹

Hedrin really works on real children

A clinical trial conducted on 36 children in Turkey in April and May 2008 demonstrated that Hedrin has 97% effectiveness.²

To minimize the opportunites for re-infestation the trial was conducted in an isolated community.

irritant graph

Safety

Hedrin is an odourless, colourless formulation which does not contain pesticides. Because it is not absorbed through the skin, it is suitable for use on children as young as six months. Hedrin does not contain any solvents which could be problematic to people with asthma.¹

Hedrin contains Dimeticone and Cyclomethicone silicones which are proven to be well tolerated and already widely used in the manufacture of cosmetics and toiletries.

Resistance

In some areas of the country, head lice have become resistant to many existing treatments which may result in infestations within schools and communities taking longer to eradicate.³

However, because Hedrin works in a purely physical way, resistance is not a factor and efficacy is not diminished even in lice resistant to other treatments.

There is no need to try different treatments for head lice because Hedrin can be used again and again.

 

Hedrin 4% lotion contains dimeticone
Always read the label
References:
1. From clinical trial published in BMJ, 18 June 2005; 330: p1423-1425
2. Data on file
3. From clinical trial published by Downs et al. Br J Dermatol 2002 Jan; 146(1)88-93